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Abstract
Human Papilloma Virus (HPV) affects many members of the community. To 
better educate the community in a participatory manner, engaging those outside of 
the health care arena is necessary. To prevent the spread of the disease in the United 
States, reaching the parents of children at the vulnerable age of 9–11 years of age 
is critical. The barriers to education of parents and children around the spread of 
a sexually transmitted disease are vast and difficult to overcome. However, the use 
of proven vaccinations give healthcare providers and community advocates the 
main tool for prevention of the spread of the disease. It is often taboo to discuss 
anything related to sexual promiscuity or sexual activity in the United States in the 
public schools. The biggest myth includes the fear parents and grandparents have is 
that if HPV is talked about, then the child may become sexually active sooner. This 
myth needs to be challenged with science and reality including taking on the those 
vehemently opposed to vaccines, known as “Anti-Vaxers” that obstruct vaccine edu-
cation. The strategies utilized in public health outreach to the community should 
be reviewed and uniquely developed for each diverse community to overcome the 
challenges in the prevention of HPV.
Keywords: Human Papilloma Virus, HPV Vaccines, Preventable Cancers, Vaccine 
Hesitancy, Community Education, HPV Vaccine Rates in the United States
1. Introduction
Human Papilloma Virus (HPV) is a sexually transmitted disease that is found 
in multiple organs in both male and female patients. The role of the provider in 
this case is extremely vital in reducing the spread of the disease and encouraging 
vaccines for prevention of cancers. HPV is the one virus that has over 200 variants, 
which has an effective vaccine regimen available and provides coverage to eliminate 
the risk for fatal cancers [1]. Thus, it would seem to be an obvious step for children 
ages 9–11 years of age and those 11–45 years of age to receive the vaccine, yet that is 
not the case [2]. Less than 30% of children actually receive the vaccine and often, 
the second dose is avoided.
This vaccine hesitancy is a global issue in that some children live in poverty and 
do not have access to this preventable cancer vaccine and in addition, those children 
with high socio-economic statues refusing to be vaccinated at the advice of their 
parents. With regard to those 11–45 years of age, often this age group has not been 
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fully educated about the concern over HPV infection and have concerns that they 
may get the disease.
Lastly, parental and grandparent vaccine hesitancy is due in part to lack of 
knowledge and concerns that the child may become promiscuous when vaccinated. 
Dispelling all of the myths surrounding HPV and the vaccine makes it difficult at 
best for providers to do due diligence in educating and preventing HPV. Which is 
quite distressing when over 13,00 cases of cervical cancers are diagnosed yearly in 
the United States (U.S.) and thousands of fatal cancers could be prevented [3].
This chapter outlines and provides the background including the incidence, 
prevalence, etiology, pathology, and health promotion measures of HPV. To appre-
ciate HPV an understanding of regular screening and clinical practice guidelines 
are presented. The importance of health promotion and prevention is outlined. 
The goal of this chapter is to review the management and care to prevent HPV 
and subsequent complications, as well as present HPV vaccine rates, HPV vaccine 
hesitancy, and strategies to provide prevention at the community level.
1.1 Prevalence and incidence of HPV
As the fourth most common cancer, cervical cancer (CC) is a global health 
issue [4]. It is estimated that 75% of women will contract a HPV infection during 
their lifetime [5]. The annual incidence rate in the United States is 14 million [6]. 
A notable variability in the incidence rates of HPV exist worldwide. So, to are the 
disparities in detection and death of HPV. Tanzania reports 10,000 cases with 7000 
death per year [4]. In Korean women, CC ranks as the seventh most common cancer 
[7]. As a result, the pathological manifestations of HPV may occur in the genital 
region and oral cavity [5]. Uterine cervical cancer incidence is approximately 
600,000 cases per year. In oral pathogenesis, HPV 16 is likely to the primary cause 
accounting for 90% of malignant neoplasms [5].
According to the Centers for Disease Control (CDC), 40 out of the over 200 
types of HPV can infect the genital region [8]. Despite being self-limited, asymp-
tomatic, or unrecognized, sexual activity persons are likely to have become infected 
at least once. The most common types of oncogenic HPV, specifically 16 and 18, are 
responsible for the development of cervical, vulvar, vaginal, penile, anal, and oral 
pharyngeal cancer. Lower risk HPV type 6 and 11 are associated with respiratory 
papillomatosis and genital warts [8].
The prevalence of oral HPV in the United States between 2011 and 2014 was 
7.3% in adults aged 18–69. During the same time frame, non-Hispanics saw a 
2.9% rate and non- Hispanic black adults was 9.7% in comparison to 7.3% in non- 
Hispanic whites and 7% in Hispanic adults. Low prevalence rates occurred among 
non- Hispanic Asian women with no significance differences noted in non-Hispanic 
white, non-Hispanic black and Hispanic women. Overall, oral HPV was highest in 
men within each race and Hispanic group [9].
1.2 Most vulnerable populations that acquire HPV
According to the World Health Organization, greater than 85% of the 300,000 
reported deaths from CC occur in countries with low to middle income. These 
rates are largely due to vaccination programs and screening practice in countries 
with higher income earnings [10]. Efforts to reach vulnerable populations are 
now distempered by the ongoing global pandemic due to the novel coronavirus 
(COVID-19), delaying and disrupting routine immunizations impinging acces-
sibility, furthering inequalities of health care potentiating healthcare consequences 
globally [11].
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2. The historical perspective of HPV
Nearly 528,000 women are diagnosed with cervical cancer each year with nearly 
half of them deceased [12]. The authors suggest that nearly 80% of the cases are 
found in third world countries are lacking the resources to battle this number of 
deaths. The evolution of (HPV) in the world is multifactorial leaving women in 
vulnerable populations more likely to contract one of the over 200 types most often 
through sexual transmission. The higher risk for women is due in part to the factors 
that lead to spread of HPV infection. Namely, early age at marriage, intercourse, 
pregnancy, and use of hormonal contraceptives [12]. Nearly 75% of adults that are 
sexually active have the disease without symptoms.
2.1 The evolution of HPV and types
There are over 200 types of HPV with 14 strains considered to be associated 
with cervical cancer [13]. Nearly 80 million people in the United States have been 
infected with most clearing the infection without incident [14]. In addition, these 
authors suggest that there has been a surge in oropharyngeal cancers related to HPV 
infection with the more notorious strains as the culprit [14].
2.2 Sites of origin of HPV
HPV is drawn to squamous epithelial cells and these are often found on mucosa 
such as skin and moist areas. HPV is most commonly found in the female cervix, 
however other sites of infection include those organs with similar tissue qualities 
such as the oropharynx, tonsillar tissue, soft palate, penis, and anus as examples. 
HPV tends to also live in the vagina, nose, nasopharynx, trachea, bronchi, and 
inner eyelid [15]. Frequently, HPV lives on the skin in the form of warts, however 
these growths can appear inside the organs described. Prevention of spread of 
anogenital warts is critical to decreasing the progression of cancer in males and 
females alike [16].
2.3 The diagnosis of HPV
The diagnosis of HPV is completed by performing a Papanicolaou (Pap) screen-
ing to identify infected cervical tissue [17]. This screening method first utilized in 
1950’s remains a gold standard for diagnosis. Cervical cancer remains the 4th most 
common cause of cancer in women globally [18]. The American Cancer Society 
(ACS) recommends that cervical cancer screening should begin at age 25 for women 
with an HPV test every five years using the U.S. Food and Drug Administration 
(FDA) tests only [15]. Those with higher risks such as immunocompromise include 
patients with HIV infection, organ transplant, or long term use of steroids [15]. If 
the patient has had a total hysterectomy with cervix removal and are cancer free are 
exempt from this testing.
2.4 Risks for preventable cancers
Cervical cancer evolves in four major steps, which include infection, persistence, 
progression, and invasion [18]. When the patient presents to clinic with oropharyn-
geal growths on the tongue or soft palate, a biopsy of the site should be performed 
and a follow up appointment should be scheduled once the diagnosis is confirmed. 
Most of the 230 genotypes of HPV cause no harm and resolve asymptomatically 
without the patient noticing with 40 genotypes known to be high risk [19]. Genital 
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warts are tumors found caused by HPV, are the most common sexually transmit-
ted disease, and generally are benign [19]. Risk factors for genital warts include: 
number of partners, barrier contraception use, young age at first encounter, 
circumcision, and male sexual behavior [19]. This high rate of transmission results 
in infection of multiple partners including females.
However, the clinician should be aware that correlating lymph node enlargement 
may require further biopsy to assure that squamous cell carcinoma is not in the 
tissue or lymph nodes. While most head and neck cancers are caused by squamous 
cell carcinoma and found historically in smoker, drinker, males >50 years of age, 
more recently it has been found in women in the oropharynx. This is occurring 
more often in the last decade as teens and young women engage in oral sex as a 
means to prevent pregnancy. In addition, males having sex with males are in a high 
risk category for this type of cancer due to multiple partners, as well as high risk for 
genital warts and anogenital cancer [19]. Recently, an anal Pap smear was created to 
help diagnose HPV in males having sex with multiple male partners. Recently, HPV 
is a culprit linked to urothelial bladder cancer as well [20].
3. Current treatments for HPV
A quadrivalent vaccine for HPV was first recommended by a sub-committee of 
the (CDC) in the United States known as the Advisory Committee on Immunization 
Practices (ACIP) in 2006 [21]. In 2009, a bivalent was available and in 2015, non-
valent HPV vaccine was created and is the mainstay in HPV vaccination today. 
To date, the vaccine rates among girls ages 13–17 years of age remains quite low 
at nearly 42%, while boys in the same age group are worse at a rate of 28% [21]. 
Pediatricians and mid-level providers spend an inordinate amount of time work-
ing to educate families regarding this cancer prevention vaccine, yet compliance 
continues to be dismal. Adults should be vaccinated up until 45 years of age.
3.1 The target age group
The WHO Director in 2018, committed to eliminating cervical cancer with a 
significant goal of a 90% immunization rate in girls 15 years of age by 2030 [10]. 
Additionally, the Healthy People 2025 national goals in the U.S. continue to advocate 
for improved vaccine completion numbers. Approximately 70% of the global target 
population includes adolescent girls, ages 9–14, living in geographic regions without 
an immunization program for HPV prevention [21]. Adults less than 45 years of age 
are encouraged to take the vaccine.
3.2 Vaccine hesitancy
According to the WHO, if 70% vaccination coverage is achieved in low and 
middle income countries, approximate 4 million deaths could be prevented [10]. 
However, despite national recommendations, vaccine hesitancy often ensues [21]. 
In 2010 an estimated 14% of teenage girls in the USA completed and received all 3 
doses, noting parental hesitancy as the primary reason for lack of follow through. 
One concern being the public policy mandate resulting in suspicion on the part 
of the parents. Parental opposition stems primarily from compulsory vaccination 
of their children citing trust and safety for the reluctance to pursue or complete 
the protocol. Several states in the U.S. require the HPV series to attend school, 
however, religious exemptions abound and this has not significantly increased the 
vaccination rate [22].
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Knowledge served as a basis for hesitancy to vaccinate. However, parents with 
the higher levels of education tend to research the topic and decided against vac-
cination. Those with lower education levels tended to base decisions to vaccinate 
due to provide recommendation or encouragement opposed pursing knowledge 
or information regarding disease prevention with vaccination adherence [22]. 
Patient navigators to increase the vaccination rates and found that white patients 
are less likely to initiate the HPV vaccine than other ethnicities, however once ini-
tiated they were more likely to finish the series [22]. Rural parents were much less 
likely to encourage HPV vaccines as compared to their urban counterparts [13]. 
Women in the U.S. in general are basically poorly informed about HPV overall 
and found therefore, that provider education should target Non-Hispanic Blacks, 
lower level educated women, and those younger than 65 years of age. Beliefs about 
the efficacy of the vaccine to prevent cervical cancer remain a barrier to increased 
vaccine rates overall [22].
Parental attitudes toward vaccination of an STI factors into the decision-making 
process regarding vaccination prior to FDA approval. Several studies conducted 
demonstrated favorable attitudes in the USA and UK and accepting vaccination of 
their children. Specifically noting a mother’s sexual values were secondary com-
pared to overall vaccination attitude. In addition, social aversion to vaccination was 
not seen across various religions groups [23].
4. Community outreach
Cancer screening efforts are an ongoing effort to take the screening tools out 
to the community [3]. Educational outreach to vulnerable communities is an 
incredibly important method of reaching underserved groups. Often, vulnerable 
and underserved people are fearful of government institutions such as schools, 
social security, hospitals, and the police. The marginalized people in society have 
frequently been unsuccessful in navigating the system to obtain access to critical 
resources. In the case of Immigrants, the concern surrounds deportation or criminal 
charges. To overcome these barriers to educating and serving the public, healthcare 
providers are placed in the position of being more creative in how outreach is 
managed.
4.1 American Cancer Society (ACS) efforts
The American Cancer Society (ACS) has for decades provided funding, 
outreach, and resources to all patients in the U.S., as well as their regions and 
individual chapters. In the last decade, ACS has worked specifically to increase 
the knowledge base of parents, grandparents, and youth regarding the impor-
tance of cancer prevention, specifically for HPV. U.S. national immunization 
coalitions have devoted large amounts of time, effort, and funding to provide 
outreach for the public in an effort to prevent HPV. In 2014, a documentary about 
HPV and cervical cancer was produced in Hollywood called “Someone You Love: 
The HPV Epidemic.” This documentary was shared at a conference in 2016 in 
Indianapolis, Indiana in the U.S. for a national meeting of all U.S. immunization 
coalitions. Soon, it spread throughout the U.S. as a tool for HPV prevention for 
youth and parents. It’s real life powerful true stories of women that suffered and 
some died from cervical cancer caused by HPV. Other efforts in Maui, Hawai’i 
include having young cancer survivors assist in Relay for Life and ACS outreach 
events to speak candidly to youth about what HPV is and how disenchanting 
cancer treatment is along with the burden of fearing that the cancer may return. 
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Once the youth are aware of what the road for a cancer patient is like, they may 
not realize that there is one cancer that is preventable, and that is by vaccination 
against HPV.
5. Conclusion
Human Papilloma Virus (HPV) is the most common sexually transmitted 
disease that is found in in both male and female patients. The role of the provider 
in this case is extremely vital in reducing the spread of the disease and encouraging 
vaccines for prevention of cancers. HPV is the one virus that has over 200 variants, 
which has an effective vaccine regimen available and provides coverage to eliminate 
the risk for fatal cancers [1]. Thus, it would seem to be an obvious step for children 
ages 9–11 years of age and those 11–45 years of age to receive the vaccine, yet that is 
not the case [2]. Less than 30% of children actually receive the vaccine and often, 
the second dose is avoided.
Strategic elements to assist in global vaccination efforts include financial 
investment on a global level, enhancement of supply, single dose schedules, and 
effective social marketing [24]. Use of social media platforms to increase aware-
ness of the notion that a vaccine preventable cancer such as cervical cancer may 
be the wave of the future. Without global concerted efforts to increase the vac-
cination rate to achieve herd immunity, the fight against HPV infection and the 
subsequent needless suffering and death will continue to occur.
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